Navigation Links
Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
Date:5/17/2010

Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

Cambridge, Mass. (PRWEB) May 17, 2010 -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1 /2 clinical study combining MM-111 with Herceptin® (trastuzumab) in patients with advanced Her2 positive breast cancer.

MM-111 is a bi-specific antibody that targets tumor cells over-expressing ErbB2/HER2. MM-111 is designed to inhibit the signaling between ErbB2/HER2 and ErbB3/HER3 thus disabling the phosphatidylinositol 3-kinase (PI3K) pathway and preventing tumor proliferation.

“Our team is quite excited to test this combination in clinical trials given the preclinical data we have produced showing that MM-111 and Herceptin® have very complementary mechanisms of action,” said Clet Niyikiza, Ph.D., Executive Vice President of Development at Merrimack. “We believe that by combining the two candidates, we have the potential to treat a number of HER2 positive breast cancer patients who are not benefiting from current treatments.”

The Phase 1 /2 study will initially evaluate the human safety and pharmacokinetics of MM-111 in combination with Herceptin® and establish a safe regimen. The Phase 2 portion of the study will then investigate the regimen’s efficacy in the advanced Her2 positive breast cancer patient population. The trial is based on preclinical work showing that MM-111 and Herceptin® positively combine to inhibit the growth of ErbB2 over-expressing breast cancer cells. The Gabrail Cancer Center in Canton, Ohio, Huntsman Cancer Institute in Salt Lake City, Utah, and the Massachusetts General Hospital in Boston, Massachusetts, will part
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Merrimack to Present Pre-Clinical Data on MM-121 and MM-111 at the 101st Annual Meeting of American Association for Cancer Research (AACR)
2. Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
3. Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance
4. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
6. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
7. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
8. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
9. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
10. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
11. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... and SHENZHEN, China , July ... LTD, (BGI Tech), a subsidiary of BGI, the ... launch of a new human whole exome sequencing ... newly offered service includes in-depth bioinformatics analysis and ... until December 31, 2014. Complete ...
(Date:7/22/2014)... Ore. , July 22, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today announced that ... before the open of U.S. financial markets on July ... Semler will host a conference call at 11 a.m. ...
(Date:7/22/2014)... , July 22, 2014  United Therapeutics Corporation ... it will release its second quarter 2014 financial ... 2014. United Therapeutics will host a ... 9:00 a.m. Eastern Time.  The teleconference is accessible ... A rebroadcast of the teleconference will be available ...
(Date:7/22/2014)... Biofeedback – When a behavioral ... selecting medication to best treat it can become a ... using electroencephalography (EEG) can help predict which medicine will ... of adverse drug events. , The article “Medication ... current issue of the journal Biofeedback offers evidence that ...
Breaking Biology Technology:BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3Semler to Report Second Quarter 2014 Financial Results and Host Conference Call on July 25, 2014 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3
... , SHANDONG , ... YCT,International Group, Inc. ("China YCT" or the "Company") (OTC Bulletin ... the State Intellectual,Property Office of the People,s Republic of ... Spring Pharmaceutical Co.,Ltd., for "a unique method of making ginkgo ...
... soon be sporting RFID tags to improve their safety. ... Ontario Centres of Excellence (OCE) are undertaking a $1.4 ... can be used to notify subway vehicles of the ... "Our customers have asked us if we could ...
... ... University,s R&D Facility , ... Boston, MA (Vocus) January 21, 2010 -- The University of Massachusetts Boston today ... sample preparation instruments, has moved its research and development operations to the university,s ...
Cached Biology Technology:China YCT International Group, Inc. Announces That the State Intellectual Property Office of the People's Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd. 2China YCT International Group, Inc. Announces That the State Intellectual Property Office of the People's Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd. 3RFID tags to boost transit worker safety 2UMass Boston's Venture Development Center Announces New Bio-Science Partner 2UMass Boston's Venture Development Center Announces New Bio-Science Partner 3
(Date:7/22/2014)... genus of planthopper known as Conosimus, which now includes ... in the southern part of the Iberian Peninsula in ... appears in the open-access Journal of Insect Science ... Conosimus baenai , has been named after Manuel ... taxonomy of Iberian Hemiptera. , Conosimus baenai ...
(Date:7/21/2014)... Jocelyn Millar , a professor of entomology ... of Chemistry at the University of California, Riverside, ... by the International Society of Chemical Ecology ( ISCE ... Silver Medal is the society,s highest honor. It ... contributions to chemical ecology, the study of chemicals that ...
(Date:7/21/2014)... tracking to monitor seals, every movement, researchers have shown ... drawn to offshore wind farms and pipelines. Those man-made ... grounds, according to a study published in the Cell ... , "I was shocked when I first saw ... Sheringham Shoal," an offshore wind farm in the United ...
Breaking Biology News(10 mins):UC Riverside entomologist receives international honor for chemical ecology contributions 2Seals forage at offshore wind farms 2
... years of research over five degraded landscapes in the National Park ... that field mice base their diet on holm oak and pine ... scrubland in the forests. The trees in the ... predators which are impeding their expansion over the mountains. In 98.5% ...
... A University of Leicester-led study may have uncovered the ... older people with high blood pressure, when compared to other ... by Bryan Williams, Professor of Medicine at the University of ... in the prestigious Journal of the American College of ...
... A new policy paper by Rice University,s Baker ... the size and influence of noncommercial traders, or "speculators," ... by the Commodities Futures Modernization Act of 2000. Speculators ... positions in the U.S. oil futures market, compared with ...
Cached Biology News:Small rodents encourage the formation of scrubland in Spain 2Beta-blockers and stroke -- new insights into their use for older people 2Study: Oil speculators dominate open interest in oil futures 2Study: Oil speculators dominate open interest in oil futures 3
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
... Technologys R.A.P.I.D. System (Ruggedized Advanced Pathogen ... PCR thermocycler designed for field hospitals, ... In addition to its ruggedness, it ... and specify as the LightCycler instrument. ...
Application: For use as a carrier in nucleic acid purification and precipitation. Physical form: Solution in 10 mM Tris HCl, pH 7.4, 1 mM EDTA Concentration: 9-11 mg/mL Physical Form: buffered aqu...
Biology Products: